Want to see TSE:ARCH full AI Analyst Report?
ARCH Stock Chart & Stats
C$0.87
-C$0.02(-2.30%)
At close: 4:00 PM EDT
C$0.87
-C$0.02(-2.30%)
Day’s Range― - ―
52-Week RangeC$0.39 - C$1.75
Previous CloseN/A
Volume14.22K
Average Volume (3M)43.97K
Market Cap
C$55.03M
Enterprise ValueC$36.94M
Total Cash (Recent Filing)C$436.76K
Total Debt (Recent Filing)C$2.73M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding67,933,290
10 Day Avg. Volume31,059
30 Day Avg. Volume43,967
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)-21.63
Price to Sales (P/S)0.00
P/FCF Ratio-53.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing LossesA reduction in net loss indicates operational progress and tighter cost control versus the prior annual period. This improves near-term cash runway and raises the likelihood management can advance clinical programs longer without immediate dilutive raises, supporting program continuity.
Debt ReductionLower nominal debt materially reduces financing and refinancing risk for a small clinical-stage biotech. Reduced leverage eases cash interest and covenant pressure, improving financial flexibility to fund trials or negotiate partner deals versus prior-year obligations.
Platform & Partnership ModelA platform-based antibody discovery model with an explicit licensing/partnership path is durable for clinical-stage firms: it enables non-dilutive funding, risk-sharing on late-stage development and commercialization, and multiple value-creation avenues per asset.
Bears Say
No Current RevenueAbsence of product revenue means the company cannot self-fund operations from commercial cash flows. That structural reliance on financing, milestones, or partners increases dilution and execution risk over the medium term if clinical or partnership progress stalls.
Negative EquityPersistently negative shareholders' equity and very small asset base imply a thin capital cushion and elevated solvency risk. This weak balance sheet constrains strategic options, reduces negotiating leverage with partners, and increases the likelihood of dilutive recapitalization if cash needs persist.
Ongoing Cash BurnNegative operating and free cash flow show the company is burning cash to advance programs. Volatile FCF trends and continued negative OCF mean management will likely need external funding within months to sustain trials, increasing financing and execution risk for long-term development.
Arch Biopartners News
ARCH FAQ
What was Arch Biopartners’s price range in the past 12 months?
Arch Biopartners lowest stock price was C$0.39 and its highest was C$1.75 in the past 12 months.
What is Arch Biopartners’s market cap?
Arch Biopartners’s market cap is C$55.03M.
When is Arch Biopartners’s upcoming earnings report date?
Arch Biopartners’s upcoming earnings report date is Aug 27, 2026 which is in 25 days.
How were Arch Biopartners’s earnings last quarter?
Arch Biopartners released its earnings results on Jun 02, 2026. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.
Is Arch Biopartners overvalued?
According to Wall Street analysts Arch Biopartners’s price is currently Overvalued.
Does Arch Biopartners pay dividends?
Arch Biopartners does not currently pay dividends.
What is Arch Biopartners’s EPS estimate?
Arch Biopartners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Biopartners have?
Arch Biopartners has 67,933,290 shares outstanding.
What happened to Arch Biopartners’s price movement after its last earnings report?
Arch Biopartners reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.769%.
Which hedge fund is a major shareholder of Arch Biopartners?
Currently, no hedge funds are holding shares in TSE:ARCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arch Biopartners Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.73%
Trailing 12-Months
Company Description
Arch Biopartners
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Technical Analysis
Satellos Bioscience
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―